REGENERX BIOPHARMACEUTICALS, INC.: 10-Q filed 2015-11-13

Name: REGENERX BIOPHARMACEUTICALS, INC.: 10-Q filed 2015-11-13
Creator: REGENERX BIOPHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What REGENERX BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2015-11-13 (fiscal Q3 2015): 29 published measures, 82 facts as tagged in accession 0001144204-15-065334.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-13
Fiscal period: fiscal Q3 2015
Accession: 0001144204-15-065334 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All REGENERX BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	711,230	USD
At 2014-12-31	949,191	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-09-30	6,841,796	USD
At 2014-12-31	2,660,810	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	-6,130,566	USD
At 2014-12-31	-1,711,619	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	659,715	USD
At 2014-12-31	844,043	USD
At 2014-09-30	1,240,934	USD
At 2013-12-31	6,306	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-1,129,552	USD	92
2015-01-01 to 2015-09-30	-4,610,253	USD	273
2014-07-01 to 2014-09-30	123,402	USD	92
2014-01-01 to 2014-09-30	-2,220,480	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	1,077	USD	273
2014-01-01 to 2014-09-30	11,606	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	5,510	USD	92
2015-01-01 to 2015-09-30	50,510	USD	273
2014-07-01 to 2014-09-30	0	USD	92
2014-01-01 to 2014-09-30	0	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-104,414,608	USD
At 2014-12-31	-99,804,355	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	101,640,092	shares	92
2015-01-01 to 2015-09-30	101,489,792	shares	273
2014-07-01 to 2014-09-30	95,972,377	shares	92
2014-01-01 to 2014-09-30	90,446,617	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	101,640,092	shares	92
2015-01-01 to 2015-09-30	101,489,792	shares	273
2014-07-01 to 2014-09-30	107,655,711	shares	92
2014-01-01 to 2014-09-30	90,446,617	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-0.01	USD/shares	92
2015-01-01 to 2015-09-30	-0.05	USD/shares	273
2014-07-01 to 2014-09-30	0	USD/shares	92
2014-01-01 to 2014-09-30	-0.02	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-0.01	USD/shares	92
2015-01-01 to 2015-09-30	-0.05	USD/shares	273
2014-07-01 to 2014-09-30	0	USD/shares	92
2014-01-01 to 2014-09-30	-0.02	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	11,376	USD
At 2014-12-31	12,871	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	183,207	USD	273
2014-01-01 to 2014-09-30	135,840	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-384,976	USD	92
2015-01-01 to 2015-09-30	-1,326,547	USD	273
2014-07-01 to 2014-09-30	-413,803	USD	92
2014-01-01 to 2014-09-30	-1,183,374	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	694,102	USD
At 2014-12-31	930,568	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	43,576	USD	92
2015-01-01 to 2015-09-30	129,307	USD	273
2014-07-01 to 2014-09-30	46,991	USD	92
2014-01-01 to 2014-09-30	139,177	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	354,743	USD
At 2014-12-31	409,619	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	162,310	USD
At 2014-12-31	232,610	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	390,486	USD	92
2015-01-01 to 2015-09-30	1,377,057	USD	273
2014-07-01 to 2014-09-30	413,803	USD	92
2014-01-01 to 2014-09-30	1,183,374	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	48,714	USD	92
2015-01-01 to 2015-09-30	162,485	USD	273
2014-07-01 to 2014-09-30	93,015	USD	92
2014-01-01 to 2014-09-30	315,521	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	101,640,092	shares
At 2014-12-31	101,316,580	shares

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2015-09-30	87,963	USD
At 2014-12-31	85,392	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2015-09-30	5,752	USD
At 2014-12-31	5,752	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-09-30	192,433	USD
At 2014-12-31	177,009	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2015-09-30	34,387	USD
At 2014-12-31	86,525	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	341,772	USD	92
2015-01-01 to 2015-09-30	1,214,572	USD	273
2014-07-01 to 2014-09-30	320,788	USD	92
2014-01-01 to 2014-09-30	867,853	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	2,571	USD	273
2014-01-01 to 2014-09-30	3,270	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	-70,300	USD	273
2014-01-01 to 2014-09-30	-262,988	USD	273

Inspect the source

Entity: REGENERX BIOPHARMACEUTICALS, INC. / CIK 0000707511
Captured: 2026-09-22 19:29 UTC
SEC response SHA-256: ffc4eb5988984f6f0271e31d8cf8024b0343b848cad3a73089a36cab28954e4d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000707511.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))